Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05986851 · ClinicalTrials.gov registry record · Phase 2
Azeliragon in MGMT Unmethylated Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by Cantex Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT05986851 is a Phase 2 study of Glioblastoma that is active but no longer recruiting, run by Cantex Pharmaceuticals. The registered enrollment target is 30 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (72% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT05986851, a Phase 2 study of Glioblastoma, is active but no longer recruiting, sponsored by Cantex Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma. Glioblastoma is a type of brain cancer that grows quickly and can invade and destroy healthy tissue. There's no cure for glioblastoma, which is also known as glioblastoma multiforme. Treatments, including surgery, radiation, and chemotherapy might slow cancer growth and reduce symptoms. New treatments of glioblastoma are needed.
Conditions Studied
Interventions
- DRUG Azeliragon
Study Locations (8)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Florida
- Miami Cancer Institute - Baptist Health - Miami
Michigan
- Corewell Health - Royal Oak
Missouri
- Washington University in St. Louis - St Louis
New York
- Lenox Hill Hospital - New York
Oklahoma
- The University of Oklahoma Health Science Center - Oklahoma City
Utah
- University of Utah Health Huntsman Cancer Center - Salt Lake City
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-09-12 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05986851
The ClinicalTrials.gov registry entry for NCT05986851 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (72% lower). The listed sponsor is Cantex Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Azeliragon is the first listed.
NCT05986851 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT05986851 about?
NCT05986851 is a clinical study titled "Azeliragon in MGMT Unmethylated Glioblastoma". This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma. Glioblastoma is a type of brain cancer that grows quickly and can invade and destroy healthy tissue. There...
What is the current status of trial NCT05986851?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-09-12. Estimated completion is 2025-06-30.
What conditions does trial NCT05986851 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT05986851?
The interventions under investigation include: Azeliragon (DRUG).
Who is sponsoring clinical trial NCT05986851?
This trial is sponsored by Cantex Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05986851 being conducted?
This trial has 8 study locations across Colorado, Florida, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.